Jump to section
To invest in scientific innovation to create transformative medicines for people with serious diseases.
Vertex is a biotechnology company that supports the research and discovery of novel medicines for life-threatening and hard-to-treat diseases. Founded back in 1989, it has achieved many successes over the years including developing breakthrough medicines to treat the underlying cause of cystic fibrosis, and winning awards such as the Robert J. Beall Therapeutics Development Award.
Though the company's specific approach is guarded, Vertex claims to leverage a strong toolkit of technologies, combining this with expertise in the field to push for faster development cycles and more effective results. It has, currently in development, a number of possible treatments for the likes of sickle cell disease, kidney disease, and type 1 diabetes.
Boasting a strong financial year in 2023, the company shows no signs of stopping as it pursues further accreditations for its existing medicines, and moves forwards with development pipelines for possible future products.
Steph
Company Specialist at Welcome to the Jungle
Mar 2009
$2.4m
LATE VC
Jul 1989
$5.8m
LATE VC
This company has top investors
Reshma Kewalramani
(CEO & President, not founder)Began working for the company in 2017 as an SVP, going on to become EVP and Chief Medical Officer before taking up the roles of CEO and President. Prior to Vertex, they spent 12 years at Amgen, ultimately as VP (Head US Medical Organization).